ESTRO 2025 - Abstract Book

S1365

Clinical - Lung

ESTRO 2025

In univariate analysis, correlation between RP of Grade 2 or higher and V5, V20, MLD, LLP for V5 and V20 was investigated. Significant correlations were found for V20 (p < 0.01), MLD (p = 0.02), and LLP for V5 (p = 0.01). In multivariate analysis of the five factors, including V20, MLD, LLP for V5, age, and sex, LLP for V5 was identified as an independent predictive factor for RP of Grade 2 or higher (p = 0.02). Next, to investigate correlations of V5 for total lung and LLP for V5 with RP, patients were divided into three groups based on ROC analysis cut-off values: Group A (low V5 and low LLP for V5), Group B (either low V5 with high LLP for V5, or high V5 with low LLP for V5), Group C (high V5 and high LLP for V5). A significant difference was observed between Group C and the other groups (p=0.01).

Conclusion: Lower lobe proportion for V5 is associated with RP of Grade 2 or higher.

Keywords: radiation pneumonitis, lung lobe proportion in DVH

References: Tsujino K, et al. J Thorac Oncol. 2014; 9 (7): 983-990 Katsui K, et al. Cancer Med. 2020 ;9 (13) : 4540-4549 Tsukita Y, et al. Radiother Oncol. 2021; 160: 266-272

2627

Mini-Oral Dose-volume predictors of cardiac adverse events after high-dose thoracic radiation therapy for lung cancer: a systematic review and meta-analysis Médéa Locquet 1 , Sophie Jacob 2 , Xavier Geets 3 , Charlotte Beaudart 4 1 Radiation epidemiology, Gustave Roussy/Inserm, Villejuif, France. 2 Laboratory of Epidemiology, Institute of Radioprotection and Nuclear Safety, Fontenay-aux-Roses, France. 3 Radiation Oncology Dpt, MIRO lab, Cliniques universitaires Saint-Luc, Brussels, Belgium. 4 Department of Biomedical Sciences, Namur Research Institute for Life Sciences, Clinical Pharmacology and Toxicology Research Unit, UNamur, Namur, Belgium Purpose/Objective: Lung cancer is a leading cause of cancer mortality and may require high-dose thoracic radiation therapy (RT). However, RT significantly increases the risk of radiation-induced cardiac events, such as pericarditis, cardiomyopathy, and ischemic heart diseases. Despite evidence from clinical trials showing that higher RT doses are associated with poorer survival outcomes due to these cardiac effects, data on dose-volume predictors of such events in lung cancer remain sparse. The objective was then to systematically synthesize the incidence of cardiac events following radiation therapy for lung cancer treatment and dose-volume metrics predictors of radiation therapy-induced cardiac events in lung cancer treatment. Material/Methods: This systematic review, registered on PROSPERO (CRD42024565103), adhered to PRISMA guidelines to investigate cardiac events and its dose-volume predictors following high-dose radiation therapy in adults with lung cancer. Data were extracted from longitudinal observational studies and randomized controlled trials. A comprehensive literature search was conducted across MEDLINE, Cochrane CENTRAL, and Embase, with studies selected based on predefined criteria, focusing on clinical cardiac outcomes. Data extraction followed CHARMS guidelines, and study quality was reported using the PROBAST tool. Results were synthesized narratively, with meta-analyses performed where appropriate using R software to estimate pooled effect sizes, heterogeneity, and publication bias.